Literature DB >> 3495234

Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.

B Kemmerich, K Borner, J E Pennington.   

Abstract

A murine model of bacteremic Haemophilus influenzae type b pneumonia was used to evaluate the therapeutic efficacies of the quinolone antimicrobial agents enoxacin and ofloxacin compared with those of ampicillin and chloramphenicol. Ampicillin-susceptible (AS) and ampicillin-resistant (AR) challenge strains were employed. Treatment with enoxacin or ofloxacin produced intrapulmonary killing of H. influenzae that was superior to that achieved with ampicillin (P less than 0.01 to P less than 0.001 for both AS and AR strains). Ofloxacin and enoxacin also provided killing greater than that with chloramphenicol for the AS strain (P less than 0.01 to P less than 0.001). For the AR strain, ofloxacin provided killing greater than that obtained with chloramphenicol (P less than 0.001). Survival from AS strain pneumonia was 60% in enoxacin-treated and 78% in ofloxacin-treated animals compared with 41% for chloramphenicol-treated and 23% for ampicillin-treated groups. We conclude that enoxacin and ofloxacin may be effective antimicrobial agents in treating either AS or AR strains causing H. influenzae pneumonia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495234      PMCID: PMC174743          DOI: 10.1128/AAC.31.3.417

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Susceptibility of Haemophilus influenza to ampicillin as determined by use of a modified, one-minute beta-lactamase test.

Authors:  J Escamilla
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

2.  Haemophilus influenzae pneumonia in adults.

Authors:  E D Everett; A E Rham; R Adaniya; D L Stevens; T R McNitt
Journal:  JAMA       Date:  1977-07-25       Impact factor: 56.272

3.  Hemophilus influenzae pneumonia in adults.

Authors:  R J Wallace; D M Musher; R R Martin
Journal:  Am J Med       Date:  1978-01       Impact factor: 4.965

4.  Effect of inoculum size on the susceptibility of Haemophilus influenzae b to beta-lactam antibiotics.

Authors:  V P Syriopoulou; D W Scheifele; C M Sack; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

5.  Cefamandole failure in ampicillin-resistant Haemophilus influenzae b pneumonia.

Authors:  R E Markham; R A Insel; R F Betts; R G Robertson
Journal:  South Med J       Date:  1981-02       Impact factor: 0.954

6.  Bacteremic hemophilus influenzae pneumonia in adults. A report of 24 cases and a review of the literature.

Authors:  D C Levin; M I Schwarz; R A Matthay; F M LaForce
Journal:  Am J Med       Date:  1977-02       Impact factor: 4.965

7.  Pneumonia and acute febrile tracheobronchitis due to haemophilus influenzae.

Authors:  D M Musher; K R Kubitschek; J Crennan; R E Baughn
Journal:  Ann Intern Med       Date:  1983-10       Impact factor: 25.391

8.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

9.  Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.

Authors:  S Nakamura; N Kurobe; S Kashimoto; T Ohue; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

10.  In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.

Authors:  S A Chartrand; R K Scribner; A H Weber; D F Welch; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

View more
  6 in total

1.  In vitro activities of five new quinolones against 88 genital and neonatal Haemophilus isolates.

Authors:  R Quentin; N Koubaa; B Cattier; M Gavignet; A Goudeau
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 2.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

3.  Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia.

Authors:  M Brun-Pascaud; M Fay; M Zhong; J Bauchet; A Dux-Guyot; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 4.  Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequences for therapy.

Authors:  R de Groot; G Dzoljic-Danilovic; B van Klingeren; W H Goessens; H J Neyens
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

Review 5.  Evaluation of quinolones in experimental animal models of infections.

Authors:  W M Scheld
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

6.  Spread of non-typable multiply resistant Haemophilus influenzae in a South African hospital.

Authors:  C Heney; F Berkowitz; T Baise; M Cotton; M Khoosal; S Vally; R Barriere; J Saunders; H J Koornhof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.